May. 13 at 2:45 AM
$RZLT
Q3 report keeps the bull thesis alive
Biggest takeaways:
• FDA did NOT shut down congenital HI pathway
• FDA acknowledged endpoint/behavioral challenges in SUNRIZE
• Company continuing discussions with additional analyses/data
• Tumor HI Phase 3 topline still expected 2H 2026
• Cash runway extends into 2027 (~
$120M cash)
The key point: this now looks more like a trial design/endpoint issue than “the drug doesn’t work.” If tumor HI data is strong and FDA provides a viable congenital HI path later this year, the rerating potential could be significant.
2H 2026 is shaping up to be the defining period for RZLT!!
